Mersana Therapeutics Inc. (NASDAQ:MRSN) has a beta value of 1.71 and has seen 1.23 million shares traded in the last trading session. The company, currently valued at $592.47M, closed the last trade at $6.53 per share which meant it gained $0.13 on the day or 2.03% during that session. The MRSN stock price is -27.72% off its 52-week high price of $8.34 and 58.96% above the 52-week low of $2.68. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.25 million shares traded. The 3-month trading volume is 1.09 million shares.
The consensus among analysts is that Mersana Therapeutics Inc. (MRSN) is a Buy stock at the moment, with a recommendation rating of 1.60. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.09.
Mersana Therapeutics Inc. (NASDAQ:MRSN) trade information
Sporting 2.03% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, 01/23/23 when the MRSN stock price touched $6.53 or saw a rise of 0.91%. Year-to-date, Mersana Therapeutics Inc. shares have moved 11.43%, while the 5-day performance has seen it change 7.76%. Over the past 30 days, the shares of Mersana Therapeutics Inc. (NASDAQ:MRSN) have changed 9.02%. Short interest in the company has seen 5.76 million shares shorted with days to cover at 4.68.
Wall Street analysts have a consensus price target for the stock at $16.83, which means that the shares’ value could jump 61.2% from current levels. The projected low price target is $12.00 while the price target rests at a high of $26.00. In that case, then, we find that the current price level is -298.16% off the targeted high while a plunge would see the stock gain -83.77% from current levels.
Mersana Therapeutics Inc. (MRSN) estimates and forecasts
Figures show that Mersana Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained 19.82% over the past 6 months, with this year growth rate of 6.64%, compared to 4.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 85.70% and 23.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 77,504.71%.
3 analysts offering their estimates for the company have set an average revenue estimate of $13.57 million for the current quarter. 6 have an estimated revenue figure of $7.62 million for the next quarter concluding in Dec 2022. Year-ago sales stood $11k and $11k respectively for this quarter and the next, and analysts expect sales will grow by 123,263.60% for the current quarter and 69,172.71% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -31.80% over the past 5 years.
Mersana Therapeutics Inc. is expected to release its next earnings report between February 27 and March 03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Mersana Therapeutics Inc. (NASDAQ:MRSN)’s Major holders
Insiders own 1.12% of the company shares, while shares held by institutions stand at 95.14% with a share float percentage of 96.22%. Investors are also buoyed by the number of investors in a company, with Mersana Therapeutics Inc. having a total of 193 institutions that hold shares in the company. The top two institutional holders are Orbimed Advisors LLC. with over 9.01 million shares worth more than $41.63 million. As of Jun 29, 2022, Orbimed Advisors LLC. held 9.27% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 8.88 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $41.03 million and represent 9.14% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. As of Jun 29, 2022, the former fund manager holds about 2.65% shares in the company for having 2.57 million shares of worth $11.89 million while later fund manager owns 2.32 million shares of worth $15.67 million as of Sep 29, 2022, which makes it owner of about 2.39% of company’s outstanding stock.